Stephen Furlong Sells 2,473 Shares of Neuronetics, Inc. (NASDAQ:STIM) Stock

Neuronetics, Inc. (NASDAQ:STIM) CFO Stephen Furlong sold 2,473 shares of Neuronetics stock in a transaction dated Friday, June 4th. The stock was sold at an average price of $15.00, for a total transaction of $37,095.00. Following the completion of the transaction, the chief financial officer now directly owns 257,012 shares of the company’s stock, valued at $3,855,180. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Stephen Furlong also recently made the following trade(s):

  • On Thursday, May 20th, Stephen Furlong sold 24,080 shares of Neuronetics stock. The shares were sold at an average price of $15.04, for a total transaction of $362,163.20.

Neuronetics stock opened at $16.11 on Friday. The company has a fifty day moving average of $13.03. Neuronetics, Inc. has a 1 year low of $1.70 and a 1 year high of $22.43. The firm has a market cap of $414.99 million, a PE ratio of -14.78 and a beta of 2.67. The company has a quick ratio of 12.24, a current ratio of 12.74 and a debt-to-equity ratio of 0.34.

Neuronetics (NASDAQ:STIM) last announced its earnings results on Tuesday, May 4th. The company reported ($0.31) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.31). Neuronetics had a negative net margin of 45.39% and a negative return on equity of 49.29%. On average, sell-side analysts predict that Neuronetics, Inc. will post -0.91 EPS for the current fiscal year.

A number of equities analysts recently weighed in on the stock. Canaccord Genuity restated a “buy” rating and set a $21.00 target price on shares of Neuronetics in a research report on Wednesday, May 5th. Piper Sandler reduced their price target on shares of Neuronetics from $27.00 to $25.00 and set an “overweight” rating on the stock in a research note on Tuesday, March 2nd. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Neuronetics presently has a consensus rating of “Buy” and a consensus target price of $22.50.

A number of large investors have recently modified their holdings of STIM. Thompson Siegel & Walmsley LLC purchased a new stake in Neuronetics during the first quarter worth about $73,000. Wells Fargo & Company MN grew its position in shares of Neuronetics by 14.9% during the fourth quarter. Wells Fargo & Company MN now owns 9,295 shares of the company’s stock worth $103,000 after buying an additional 1,206 shares in the last quarter. Envestnet Asset Management Inc. acquired a new position in shares of Neuronetics during the first quarter worth about $134,000. Price T Rowe Associates Inc. MD acquired a new position in shares of Neuronetics during the first quarter worth about $134,000. Finally, One68 Global Capital LLC acquired a new position in shares of Neuronetics during the fourth quarter worth about $142,000. Institutional investors own 80.55% of the company’s stock.

About Neuronetics

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.

Read More: Understanding dividend yield and dividend payout ratio

Insider Buying and Selling by Quarter for Neuronetics (NASDAQ:STIM)

Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.